Notes
See Example Scenario B for further explanation on the use of the gamma constant.
The occupancy factor of 0.25 implies that a person is present 25 % of the time at a certain distance from a source of radiation. The 5 mSv standard is based on a number of factors such as the occupancy factor, inputted into specific equations. Please see NUREG-1556, volume 9, revision 2 [9], for further guidance on these.
See calculations under Example Scenario A for an in-depth explanation on the use of the decay equation.
The 5 mSv and 33 mCi standard are based on a number of factors inputted into specific equations. Please see NUREG-1556, volume 9, revision 2 [9], for further guidance on these factors and the potential variance of patient-specific release rates.
Dose equivalence rate is different from exposure rate in that it takes into account the biological effect of different types of radiation. Exposure rate can be directly measured or determined from the radionuclide of interest and its activity.
References
Shackett P (2009) Nuclear medicine technology: procedures and quick reference, 2nd edn. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, pp 492–493
Mayo Clinic (2011) Sodium iodide I 131 (oral route). http://www.mayoclinic.com/health/drug-information/DR601253. Accessed 20 Aug 2013
Balon HR, Silberstein EB, Meier DA, et al. (2006) Society of Nuclear Medicine procedure guideline for thyroid uptake measurement. http://www.interactive.snm.org/docs/Thyroid%20Uptake%20Measure%20v3%200.pdf. Accessed 25 Aug 2013
U.S. EPA (2012) Iodine. http://www.epa.gov/radiation/radionuclides/iodine.html. Accessed 20 Aug 2013
Shleien B, Birky BK, Slaback LAJ, Birky B, Slaback LA (1998) Health physics & radiological health handbook, 3rd edn. Lippincott Williams & Wilkins, Baltimore
Health Physics Society. (2013) Regulatory dose limits. http://www.hps.org/publicinformation/ate/faqs/regdoselimits.html. Accessed 4 May 2014
US NRC (2013) § 35.75 Release of individuals containing unsealed byproduct material or implants containing byproduct material. http://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-0075.html. Accessed 4 May 2014
US NRC (2013) § 20.1301 Dose limits for individual members of the public. http://www.nrc.gov/reading-rm/doc-collections/cfr/part020/part020-1301.html. Accessed 4 May 2014
Howe DB, Beardsley M, Bakhsh SR (2008) Consolidated guidance about materials licenses. Program-specific guidance about medical uses licenses (NUREG-1556, volume 9, revision 2). http://www.pbadupws.nrc.gov/docs/ML0734/ML073400289.pdf. Accessed 4 May 4, 2014
Karesh S, Lipps M (2012) Half lives: physical, biological and effective. http://www.nucmedtutorials.com/dwhalf/effective.html. Accessed 21 Sep 2013
US FDA (2009) What are the radiation risks from CT? http://www.fda.gov/radiation-emittingproducts/radiationemittingproductsandprocedures/medicalimaging/medicalx-rays/ucm115329.htm. Accessed 21 Sep 2013
National Council on Radiation Protection & Measurements (2009) NCRP report no. 160, ionizing radiation exposure of the population of the United States. http://www.ncrponline.org/Publications/Press_Releases/160press.html. Accessed 4 June 2014
Sisson JC, Freitas J, McDougall IR et al (2011) Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid 21(4):335–346
US NRC (2009) 10 CFR 20.1003 definitions. http://www.nrc.gov/reading-rm/doc-collections/cfr/part020/part020-1003.html. Accessed 28 Aug 2013
UNSCEAR. UNSCEAR 2006 report vol. I: report to the general assembly, scientific annexes A and B. http://www.unscear.org/unscear/en/publications/2006_1.html. Accessed 11 Nov 2013
US EPA Agency (2012) Radiation protection. http://www.epa.gov/radiation/topics.html. Accessed 25 Aug 2013
NDT Education Resource Center (2012) Radiographic inspection—formula based on Newton’s inverse square law. http://www.ndt-ed.org/GeneralResources/Formula/RTFormula/InverseSquare/InverseSquareLaw.htm. Accessed 25 Aug 2013
Stanford Dosimetry. RADAR—the radiation dose assessment resource. http://www.doseinfo-radar.com/RADARDoseRiskCalc.html. Accessed 4 May 2014
International Commission on Radiological Protection (2004) Release of patients after therapy with unsealed radionuclides. Annals ICRP 34(2):v-vi, 1–79
Leslie WD, Havelock J, Palser R, Abrams DN (2002) Large-body radiation doses following radioiodine therapy. Nucl Med Comm 23(11):1091–7
Mathieu I, Caussin J, Smeesters P, Wambersie A, Beckers C (1999) Recommended restrictions after 131I therapy: measured doses in family members. Health Phys 76(2):129–36
Zanzonico PB (1997) Radiation dose to patients and relatives incident to 131I therapy. Thyroid 7(2):199–204
Barrington SF, O’Doherty MJ, Kettle AG, Thomson WH, Mountford PJ, Burrell DN, Farrell RJ, Batchelor S, Seed P, Harding LK (1999) Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. Eur J Nucl Med 26(7):686–92
Oak Ridge Institute for Science and Education. Radiation dose estimates and other compendia. http://www.orise.orau.gov/reacts/resources/dose-estimates.aspx. Accessed 4 June 2014
Acknowledgments
The authors acknowledge the following individuals for their contributions to this paper: Mr. Jim Hardeman, Georgia Poison Center, and Dr. Adam Pomerleau and Mr. John Dixon, Centers for Disease Control and Prevention.
Conflict of Interest
None
Sources of Funding
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Van Dyke, M., Punja, M., Hall, M.J. et al. Evaluation of Toxicological Hazards from Medical Radioiodine Administration. J. Med. Toxicol. 11, 96–101 (2015). https://doi.org/10.1007/s13181-014-0412-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-014-0412-5